Verastem, Inc. Files 8-K with Shareholder Votes and Disclosures
Ticker: VSTM · Form: 8-K · Filed: May 23, 2024 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, regulatory-filing, disclosure
TL;DR
Verastem filed an 8-K today covering shareholder votes, Reg FD, and other events. Check it out.
AI Summary
On May 23, 2024, Verastem, Inc. filed an 8-K report detailing several key events. The company announced the submission of matters to a vote of its security holders, disclosed information under Regulation FD, and reported other events and financial statements. The filing also confirmed Verastem, Inc.'s principal executive offices are located at 117 Kendrick Street, Suite 500, Needham, MA 02494.
Why It Matters
This 8-K filing provides important updates for Verastem, Inc. shareholders regarding upcoming votes and regulatory disclosures, impacting their understanding of corporate governance and company communications.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate events and does not appear to contain significant new risks or negative information.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
- 117 Kendrick Street, Suite 500, Needham, MA 02494 (location) — Principal Executive Offices
FAQ
What specific matters are being submitted to a vote of Verastem, Inc. security holders?
The filing indicates that matters are being submitted to a vote of security holders, but the specific details of these matters are not provided in this summary section of the 8-K.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
The Regulation FD Disclosure indicates that Verastem, Inc. is providing information to the public in a non-discriminatory manner, as required by the SEC's fair disclosure rules.
Are there any new financial statements or exhibits included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, suggesting that such documents are included, though their specific content is not detailed here.
When was Verastem, Inc. incorporated, and in which state?
Verastem, Inc. was incorporated in Delaware.
What is the primary business of Verastem, Inc. according to its SIC code?
Verastem, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 2,381 words · 10 min read · ~8 pages · Grade level 15.2 · Accepted 2024-05-23 17:24:02
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2415352d1_8k.htm (8-K) — 49KB
- tm2415352d1_ex99-1.htm (EX-99.1) — 29KB
- tm2415352d1_ex99-2img01.jpg (GRAPHIC) — 6KB
- 0001104659-24-064781.txt ( ) — 271KB
- vstm-20240523.xsd (EX-101.SCH) — 3KB
- vstm-20240523_lab.xml (EX-101.LAB) — 33KB
- vstm-20240523_pre.xml (EX-101.PRE) — 22KB
- tm2415352d1_8k_htm.xml (XML) — 4KB
07. Submission of Matters to a Vote
Item 5.07. Submission of Matters to a Vote of Security Holders. The 2024 annual meeting of stockholders (the "Annual Meeting") of Verastem, Inc. (the "Company" or "Verastem") was held in Needham, Massachusetts on May 23, 2024. At the Annual Meeting, the stockholders considered and acted upon the following proposals: Proposal No. 1 — Election of Class III Directors . By the vote reflected below, the stockholders elected the following individuals to serve as Class III directors until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Name Votes For Votes Withheld Broker Non-Votes Paul Bunn 16,597,690 161,529 3,886,307 Anil Kapur 16,407,577 351,642 3,886,307 Daniel Paterson 16,613,361 145,858 3,886,307 Michelle Robertson 16,624,861 134,358 3,886,307 There were no abstentions with respect to this proposal. Proposal No. 2 – Approval of the Amended and Restated 2021 Equity Incentive Plan (the "Amended 2021 Plan"). The stockholders voted to adopt the Company's Amended 2021 Plan. 8,715,853 shares voted for the proposal; 6,284,473 shares voted against the proposal; and 1,758,893 shares abstained from voting on the proposal. There were 3,886,307 broker non-votes on the proposal. Proposal No. 3 — The Ratification of the Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Current Fiscal Year . The stockholders voted to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year. 20,520,912 shares voted for the proposal; 112,377 shares voted against the proposal; and 12,237 shares abstained from voting on the proposal. There were [no] broker non-votes on the proposal. Proposal No. 4 — Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers . The Company's stockholders approved, on a non-binding, advisory basis, the compensation paid to t
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 23, 2024, the Company issued a press release announcing initial interim safety and efficacy results from the RAMP 205 trial of avutometinib and defactinib in combination with current standard of care in first-line metastatic pancreatic cancer, which will be presented at the upcoming American Society of Clinical Oncology ("ASCO") Annual Meeting on June 1, 2024. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events. Recent Developments RAMP 205 The Company recently announced initial interim safety and efficacy results from the ongoing dose-finding RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in patients with first-line metastatic pancreatic cancer. The initial interim results will be presented at the upcoming ASCO Annual Meeting on June 1, 2024, in a poster session from 1:30-4:30 p.m. CDT in Chicago, IL. As of a data cutoff of May 14, 2024, 41 patients had been treated in one of four dose and schedule cohort regimens of avutometinib and defactinib with gemcitabine and nab-paclitaxel: In dose level 1, six patients received 2.4 mg of avutometinib twice a week (BIW), 200 mg of defactinib twice a day (BID) for 3 weeks out of every 4 and 800 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on a schedule of day 1, day 8 and day 15. In dose level -1, 11 patients received 2.4 mg of avutometinib twice a week (BIW), 200 mg of defactinib twice a day (BID) for 3 weeks out of every 4 with 800 mg/m2 of gemcitabine and 100 mg/m2 of Nab-paclitaxel on a schedule of day 1, day 8 and day 15. In dose level 1a, 12 patients received 3.2 mg of avutometinib twice a week (BIW), 200 mg of defactinib twice a day (BID) for 3 weeks out of every 4 with 800 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on a schedule of day 1 and day 15. In dose level 2a, 12 patients received 3.2 mg of avutometinib twice a week (BIW), 200 mg of defactinib twice a day (BID) for 3 weeks out of every 4 with 1000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on a schedule of day 1 and day 15. In the dose level 1 cohort, 83% (5/6) of patients achieved a confirmed partial response. One dose-limiting toxicity of febrile neutropenia was observed in the dose level 1 cohort and the dose cohort was cleared after additional patients were evaluated. In the additional dose cohorts enrolled more recently
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: May 23, 2024 By: /s/ Da niel W. Paterson Daniel W. Paterson President and Chief Executive Officer